Peihua Lu, MD, Beijing Lu Daopei Institute of Hematology, Beijing, China, discusses the safety and efficacy results of the Phase I trial (NCT04322292) of C-CAR088 in heavily pre-treated multiple myeloma patients. C-CAR088 is an anti-BCMA CAR T-cell therapy, with a novel second-generation 4-1BB chimeric antigen receptor. Initial dose-escalation and expansion studies have shown good efficacy, with an overall response rate of over 95%. C-CAR088 was generally well tolerated, with only one occurrence of grade 3 cytokine release syndrome. No dose-limiting toxicities were observed, and the median duration of response has not yet been reached. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.